Lipella Total Cash From Operating Activities from 2010 to 2024

LIPO Stock   3.11  0.16  5.42%   
Lipella Pharmaceuticals Total Cash From Operating Activities yearly trend continues to be very stable with very little volatility. Total Cash From Operating Activities is likely to grow to about -3 M this year. During the period from 2010 to 2024, Lipella Pharmaceuticals Total Cash From Operating Activities quarterly data regression pattern had range of 3.1 M and standard deviation of  1,113,493. View All Fundamentals
 
Total Cash From Operating Activities  
First Reported
2010-12-31
Previous Quarter
-3.2 M
Current Value
-3 M
Quarterly Volatility
1.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lipella Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lipella Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.6 K, Interest Expense of 9.6 K or Selling General Administrative of 2.3 M, as well as many indicators such as Price To Sales Ratio of 176, Dividend Yield of 0.0 or PTB Ratio of 16.36. Lipella financial statements analysis is a perfect complement when working with Lipella Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Lipella Pharmaceuticals Correlation against competitors.

Latest Lipella Pharmaceuticals' Total Cash From Operating Activities Growth Pattern

Below is the plot of the Total Cash From Operating Activities of Lipella Pharmaceuticals Common over the last few years. It is Lipella Pharmaceuticals' Total Cash From Operating Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lipella Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Total Cash From Operating Activities10 Years Trend
Slightly volatile
   Total Cash From Operating Activities   
       Timeline  

Lipella Total Cash From Operating Activities Regression Statistics

Arithmetic Mean(625,534)
Coefficient Of Variation(178.01)
Mean Deviation861,484
Median(39,117)
Standard Deviation1,113,493
Sample Variance1.2T
Range3.1M
R-Value(0.75)
Mean Square Error590.4B
R-Squared0.56
Significance0
Slope(185,966)
Total Sum of Squares17.4T

Lipella Total Cash From Operating Activities History

2024-3 M
2023-3.2 M
2022-1.8 M
2021-989.3 K
2020-28.6 K

About Lipella Pharmaceuticals Financial Statements

Lipella Pharmaceuticals investors utilize fundamental indicators, such as Total Cash From Operating Activities, to predict how Lipella Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Cash From Operating Activities-3.2 M-3 M

Pair Trading with Lipella Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipella Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipella Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Lipella Stock

  0.62BMY Bristol Myers Squibb Sell-off TrendPairCorr
  0.61VTRS ViatrisPairCorr
  0.53ESPR Esperion Therapeutics Buyout TrendPairCorr
  0.49GILD Gilead SciencesPairCorr
  0.45WAT WatersPairCorr
The ability to find closely correlated positions to Lipella Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipella Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipella Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipella Pharmaceuticals Common to buy it.
The correlation of Lipella Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipella Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipella Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipella Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Lipella Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipella Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipella Pharmaceuticals Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipella Pharmaceuticals Common Stock:
Check out the analysis of Lipella Pharmaceuticals Correlation against competitors.
You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipella Pharmaceuticals. If investors know Lipella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipella Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.88)
Revenue Per Share
0.592
Quarterly Revenue Growth
0.279
Return On Assets
(0.94)
Return On Equity
(1.72)
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipella Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipella Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipella Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.